anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Airway basal cells (BC) from patients with chronic obstructive pulmonary disease (COPD) regenerate abnormal airway epithelium and this was associated with reduced expression of several genes involved in epithelial repair. Quercetin reduces airway epithelial remodeling and inflammation in COPD models, therefore we examined whether quercetin promotes normal epithelial regeneration from COPD BC by altering gene expression.
METHODS: COPD BC treated with DMSO or 1 µM quercetin for three days were cultured at air/liquid interface (ALI) for up to 4 weeks. BC from healthy donors cultured at ALI were used as controls. Polarization of cells was determined at 8 days of ALI. The cell types and IL-8 expression in differentiated cell cultures were quantified by flow cytometry and ELISA respectively. Microarray analysis was conducted on DMSO or 1 µM quercetin-treated COPD BC for 3 days to identify differentially regulated genes (DEG). Bronchial brushings obtained from COPD patients with similar age and disease status treated with either placebo (4 subjects) or 2000 mg/day quercetin (7 subjects) for 6 months were used to confirm the effects of quercetin on gene expression.
RESULTS: Compared to placebo-, quercetin-treated COPD BC showed significantly increased transepithelial resistance, more ciliated cells, fewer goblet cells, and lower IL-8. Quercetin upregulated genes associated with tissue and epithelial development and differentiation in COPD BC. COPD patients treated with quercetin, but not placebo showed increased expression of two developmental genes HOXB2 and ELF3, which were also increased in quercetin-treated COPD BC with FDR < 0.001. Active smokers showed increased mRNA expression of TGF-β (0.067) and IL-8 (22.0), which was reduced by 3.6 and 4.14 fold respectively after quercetin treatment.
CONCLUSIONS: These results indicate that quercetin may improve airway epithelial regeneration by increasing the expression of genes involved in epithelial development/differentiation in COPD.
TRIAL REGISTRATION: This study was registered at ClinicalTrials.gov on 6-18-2019. The study number is NCT03989271.
The prognosis of myocardial infarction with non-obstructive coronary arteries (MINOCA) is reported to be as worse as myocardial infarction with obstructive coronary arteries. However, its mechanical complications are still poorly understood. A 71-year-old woman developed MINOCA after ascending aortic replacement surgery. During treatment, the patient experienced cardiogenic shock due to a ventricular septal rupture (VSR). The introduction of Impella devices reduced the left-to-right shunt and improved the patient's hemodynamics. Finally, a scheduled surgical repair was performed under stable conditions. In this report, we focused on the pathophysiology of MINOCA-related VSR and discussed the effectiveness of Impella devices as a bridge to surgical repair and circulatory backup during the perioperative period.
A dry powder inhaler for pulmonary or nasal use, comprising at least an inhaler body  801  and a cartridge  803  with at least one powder compartment  805  including one dose of a drug. The body has an opening  804  shaped for receiving the cartridge  803  and the means to allow a controlled sliding movement of the cartridge  803  relative to the body  801  after mounting. The cartridge powder compartment  805  comprises at least two inlets or slits  806, 809 , at least one of which is a side inlet  809 , for the admission of air, and a compartment outlet  807  to allow filling and fluid communication with an inhalation channel  808  provided in the body  801 . In use, the patient slides the cartridge  803  relative to the body  801  from the storage position, where the inlets in the cartridge powder compartment  805  are blocked and sealed by walls comprised in the body  801 , into the inhalation position, where the compartment inlets become available for the admission of air used in the dispersion of the particles there contained and the compartment outlet  807  becomes aligned with the inhalation channel  808  in the body  801  to allow the entrainment of the dose dispersed through the device and into the desired site of action during inhalation. The addition of one or more lateral vents  809  in the cartridge powder compartments induces a turbulent and swirling flow pattern that promotes improved dispersion and entrainment. The invention affords a very economical and simple device for the delivery of high dosages of inhaled medicines.
The invention relates to the technical field of medicines, in particular to a preparation method and application of (S, E) -4- (5-hydroxy-7- (4-hydroxy-3-methoxyphenyl) hept-1-en-1-yl) phenylacetate in curcuma zedoary, wherein the preparation method comprises the following steps: (1) Pulverizing rhizome of zedoary turmeric, leaching with ethyl acetate, concentrating the leaching solution to obtain residual extract, separating the extract by 100-200 mesh silica gel column chromatography, and gradient eluting with petroleum ether-ethyl acetate mixed solution with volume ratio of 1:0-0:1 to obtain six components Fr.I-VI; (2) Repeatedly separating the components Fr. IV by HW-40F gel column chromatography, then performing 100-200 mesh silica gel column chromatography, and then performing gradient elution by using petroleum ether-ethyl acetate mixed solution with the volume ratio of 8:2, 2:1 and 1:1 to obtain 3 components Fr. IV2b 1-Fr. IV2b3; (3) Separating the component Fr. IV2b1 by using a preparative high performance liquid chromatography, and purifying by using a semi-preparative high performance liquid chromatography to obtain the target compound. The compound has alpha-glucosidase inhibitory activity and can be applied to preparing medical products with the function of reducing blood sugar.
Two single-arm open-label studies of fludarabine phosphate have been conducted in adult patients with CLL refractory to at least one prior standard alkylating-agent containing regimen. In a study conducted by M.D. Anderson Cancer Center (MDAH), 48 patients were treated with a dose of 22 to 40 mg/m2 daily for 5 days every 28 days. Another study conducted by the Southwest Oncology Group (SWOG) involved 31 patients treated with a dose of 15 to 25 mg/m2 daily for 5 days every 28 days. The overall objective response rates were 48% and 32% in the MDAH and SWOG studies, respectively. The complete response rate in both studies was 13%; the partial response rate was 35% in the MDAH study and 19% in the SWOG study. These response rates were obtained using standardized response criteria developed by the National Cancer Institute CLL Working Group and were achieved in heavily pretreated patients. The ability of fludarabine phosphate to induce a significant rate of response in refractory patients suggests minimal cross-resistance with commonly used anti-CLL agents. 

The median time to response in the MDAH and SWOG studies was 7 weeks (range of 1 to 68 weeks) and 21 weeks (range of 1 to 53 weeks), respectively. The median duration of disease control was 91 weeks (MDAH) and 65 weeks (SWOG). The median survival of all refractory CLL patients treated with fludarabine phosphate was 43 weeks and 52 weeks in the MDAH and SWOG studies, respectively.

Rai stage improved to Stage II or better in 7 of 12 MDAH responders (58%) and in 5 of 7 SWOG responders (71%) who were Stage III or IV at baseline. In the combined studies, mean hemoglobin concentration improved from 9.0 g/dL at baseline to 11.8 g/dL at the time of response in a subgroup of anemic patients. Similarly, average platelet count improved from 63,500/mm3 to 103,300/mm 3 at the time of response in a subgroup of patients who were thrombocytopenic at baseline.
Femoral nerve catheter delivering 0.0625% L- Bupivacaine: Blockade at level of Femoral crease. Identify femoral nerve. In plane lateral approach. Bolus 20 mls via needle. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad).and 5 mls injected via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
Perpendicular Group will undergo radiofrequency ablation via the approach described in Spine Intervention Society Practice Guidelines for medial branch blocks, using a 22 gauge electrode. Specifically, the target nerve will be targeted with a perpendicular approach so as the tip of electrode contact the nerve at some point of it course along the sulcus formed by the neck of superior articular process and transverse process (or sacral ala for L5) cephalad to the point it is covered by the mamillo-accessory ligament.
HIV is declining in many parts of the world, but rising in Latin America, including Brazil. The HIV epidemic in Brazil, including the number of new infections, is concentrated among sexual and gender minority (SGM) youth, including men who have sex with men (MSM) and transgender women (TGW). SGM youth in Brazil face obstacles to HIV prevention. Use of HIV pre-exposure prophylaxis (PrEP) lags far behind PrEP need in Brazil, especially among SGM youth. There is international momentum to promote PrEP as prevention and to increase access to low barrier care. Peer lay workers are a promising approach to address the unmet need for PrEP uptake and adherence among SGM youth in Brazil.

COMPrEP is a multi-site randomized controlled trial designed to determine if peer delivery of PrEP to SGM youth aged 15-24 in Brazil will increase PrEP uptake, persistence, and adherence compared to standard PrEP care provided in SGM-affirming health facilities. Eligible SGM youth (N=1400) in two municipalities in Brazil (i.e., Salvador and São Paulo) will be randomized to 1:1 to either the COMPrEP intervention arm (PrEP access through peer lay workers in community venues) or the standard care arm (PrEP access through health providers at SGM-affirming health facilities). It is anticipated that approximately 245 and 140 SGM youth will initiate PrEP in intervention and standard care arms, respectively, and these will be followed for 12 months, facilitating measurement of PrEP adherence and persistence outcomes on this subset.
Participants were to receive oral treatment with MK-3577 10 mg QD AM for 4 weeks during Period 1, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 2, followed by MK-3577 25 mg BID for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
AD is, in a word, devastating. The massive psychological and physical trauma experienced by people with dementia and their loved ones is catastrophic and incapable of overestimation. It is incumbent upon researchers and clinicians to not only better understand the etiology of this disease, but also to translate this knowledge into actionable evidence to facilitate clinical care and prevention. The MGBA serves as a major etiological factor, in both cause and potentiation of the disease process, that possesses great potential for intervention. Interventions have the greatest opportunity for success earlier in the disease pathogenesis; therefore, MCI is an ideal target for intervention to prevent progression to AD. To effectively apply knowledge of this bidirectional relationship, a clearer picture of dysbiosis relevant to cognitive decline must be identified. The inclusion of HC, MCI, and early AD allows for the detection of a dose-response relationship, which is one of Bradford Hill's criteria for causality. 1 This means we will begin to investigate causality (using one of Hill's eight criteria) in addition to association in this proof-of-concept study.

Most previous research has been done at too high a phylogenetic level to be truly informative in terms of interventions-in other words the data is too low resolution. The microbiome field was launched at the phylum/genus level for many reasons including the need to start somewhere in such a complex system. To put this in perspective, comparing a genus, such as Lactobacillus, would be akin to comparing a compilation or average of all species of the genus Homo: H. sapiens, H. habilis, H. errectus, H. heigelbergensis, H. neanderthalensis, and H. naledi. The diversity in Homo sapiens alone is staggering. How could we possibly think this is specific or high resolution enough to be clinically meaningful? Well, the research has shown that it is not. This coupled with advancements in technology (qPCR to 16S to shotgun metagenomics) has changed the landscape of the microbiome field. However, such advanced testing and understanding has yet to make it to the clinic and has largely not been applied to MCI or AD populations to date.

The sum of the evidence suggests that restoration of the gut microbiome may serve to prevent, slow, or even reverse MCI/AD. Whether this entails the use of diet, supplements, medications, etc. or some combination thereof remains to be discovered. Before an intervention can be designed, a firm grasp of the specific alterations to the gut microbiome must be identified using higher resolution than simply genus alone-we must understand species level at least, ideally strain level in many cases. Once we understand the species-level alterations, therapeutic interventions may then be implemented to determine the effect size of said interventions.
Identified is the molecule C3d as a biomarker for dengue, C3d being a fragment of protein C3, a component of the complement system, part of the innate immunity that is activated in response to the infection or deposit of immune complexes. The fragments generated by the proteolytic activity of the complement components have different biological activities: chemotaxis (C3a and C5a), opsonization (C3b), cellular lysis (C6-C7-C8-C9n), etc. C3d has an adyuvant function; it is bonded to the receptor CR2 of lymphocytes B, while the antigen is bonded to the BCR, thus increasing the production of antibodies. The proteolysis of C3 generated two fragments (C3a and C3b), C3b being subsequently cut, generating C3c and C3d. Part of C3d is released to serum. The invention describes that the serum of patients with dengue contains a higher concentration of C3d than the serum of healthy people or patients infected with HBV, HCV, Brucella abortus or Treponema pallidum. The detection and quantification o f C3d is performed by current or future methods. The invention protects the use of C3d as a biomarker in dengue and its use in the diagnosis, treatment and clinical follow up of patients.
10.1 Acute Overdosage - Human Overdose Experience

Human experience of acute overdose with NORVIR is limited. One patient in clinical trials took NORVIR 1500 mg per day for two days. The patient reported paresthesias which resolved after the dose was decreased. A post-marketing case of renal failure with eosinophilia has been reported with ritonavir overdose.

The approximate lethal dose was found to be greater than 20 times the related human dose in rats and 10 times the related human dose in mice.

10.2 Management of Overdosage

NORVIR oral solution contains 43.2% (v/v) alcohol and 26.57% (w/v) propylene glycol. Ingestion of the product over the recommended dose by a young child could result in significant toxicity and could potentially be lethal.

Treatment of overdose with NORVIR consists of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. There is no specific antidote for overdose with NORVIR. If indicated, elimination of unabsorbed drug should be achieved by gastric lavage; usual precautions should be observed to maintain the airway. Administration of activated charcoal may also be used to aid in removal of unabsorbed drug. Since ritonavir is extensively metabolized by the liver and is highly protein bound, dialysis is unlikely to be beneficial in significant removal of the drug. However, dialysis can remove both alcohol and propylene glycol in the case of overdose with ritonavir oral solution. A Certified Poison Control Center should be consulted for up-to-date information on the management of overdose with NORVIR.
A humanized monoclonal antibody against the CD34 surface antigen is provided in the present disclosure. The humanized monoclonal antibody includes a light chain variable region and a heavy chain variable region. In which, a nucleotide sequence encoding the amino acid sequence for the light chain variable region comprises a nucleotide sequence which encodes the amino acid sequence of SEQ ID No. 9 or an amino acid sequence with at least 80% sequence identity to the sequence of SEQ ID No. 9, and a nucleotide sequence encoding the amino acid sequence for the heavy chain variable region comprises a nucleotide sequence which encodes the amino acid sequence of SEQ ID No. 10 or an amino acid sequence with at least 80% sequence identity to the sequence of SEQ ID No. 10.
Sham stimulation was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator. Sham stimulation was delivered to the cerebellum for 5 seconds at 55 second intervals in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
Dry eye is a disease of the ocular surface. Severe dry eye produce symptom of discomfort in and around the eye that drastically affect life quality of the patient. OSDI index is retrieve from a questionnaire specific for these dry eye symptoms, it is an internationally accepted level to reveal the severity of Dry eye disease. One part of the symptom is pain and soreness around the eye. Hyperalgesia is an increase response to a stressful/ noxious stimulus whereas allodynia is a painful response to a normally innocuous stimulus. Our hypothesis state that Sicca Dry eye upregulated inflammatory cytokine in the eye has pre-sensitized the nociceptor nerve fiber in the cornea and orbit, therefore the normally innocuous effort of accommodation and ciliary muscle contraction produce intolerable retro-orbital eye pain, which drives the patient to seek medical attention, on presentations these patient show an elevated OSDI and Pain Index (PI).
FIELD: chemistry. ^ SUBSTANCE: invention can be used to make dental care agents. An alkali metal silicate is mixed with an acidifying agent in an amount sufficient for formation of a composition which contains silica gel particles. The obtained composition is not washed or cleaned. An alkali metal silicate and an acidifying agent are then added to the obtained composition in amounts sufficient for formation of a silica precipitate, resulting in formation of an abrasive gel/precipitate combination. Radioactive dentin abrasion (RDA) of the said combination can be equal to 95-150, 180-240, with pellicle cleaning ratio (PCR) equal to 90-160 or 20-80 with PRC between 50 and 80. The obtained abrasive silica gel/precipitate combination is used in making dental care agents. ^ EFFECT: invention enables to obtain materials with good cleaning properties with respect to tooth pellicle and lower radioactive dentin abrasion values. ^ 12 cl, 3 dwg, 14 tbl, 17 ex
The invention relates to a medicine for treating hyperthyroidism. The medicine is prepared from, by weight, 10 parts of radix bupleuri, 8 parts of radix paeoniae alba, 6 parts of clams, 9 parts of  stems and leaves of Abrus precatorius, 9 parts of Derris eriocarpa how, 12 parts of Carpesium abrotanoides, 6 parts of Buddleja officinalis, 10 parts of Dendrobium jenkinsii Wall. ex Lindl.[D. aggregatum Roxb,15 parts of Cheilesoria tenuifolia (Burm.) Trev.[Trichomanes tenuifolium Burm.] and 12 parts of callistemon rigidus. The medicine has the advantages that the radix bupleuri can get into the liver and gall meridians, yang qi is uplifted, and liver-qi stagnation is soothed; the radix paeoniae alba can retain yin with astringent and nourish blood and liver and is mixed with the radix bupleuri for use so as to tonify the liver blood and smooth liver-qi, so that the radix bupleuri is made to be uplifted and no yin-blood is consumed; the clams can get into the kidney, heat is cleared away, diuresis is promoted, and phlegm is reduced; the stems and leaves of Abrus precatorius promote production of body fluid, nourish the lung and clear away heat; the Derris eriocarpa how can regulate qi-flow for strengthening the spleen; the Carpesium abrotanoides can get into lung and liver meridians, eliminate phlegm and clear away heat and toxic materials; the Buddleja officinalis can get into the liver meridian, clear away heat, nourish the liver and cool blood; the Dendrobium jenkinsii Wall. ex Lindl.[D. aggregatum Roxb.] can moisten the lung and reduce phlegm; the Cheilesoria tenuifolia (Burm.) Trev.[Trichomanes tenuifolium Burm.] can clear away heat and toxic materials and activate blood; the callistemon rigidus can get into the lung meridian and remove wind and phlegm. The medicines are mixed for use for achieving the effects of nourishing yin, clearing away heat, decreasing internal heat, reducing phlegm and activating blood. A clinical experiment proves that the medicine can safely and effectively treat hyperthyroidism.
Methods, devices, and systems for monitoring and sharing emotion-related data from one or more users/patients connected via the internet to others or to a remote therapist. An emotion monitoring device (EMD) measures a patient's biometric data obtained from biosensors and computes emotion states relating to emotional arousal and valence. The EMD communicates the emotion data to an internet server via a wireless network. The internet server transmits the emotion data to a remote therapist. The patients' emotion states are shared with the therapist during a teletherapy interaction to compensate for the absence of in-person clinical information. The therapist may also be equipped with an EMD so that the emotion data of the patient and therapist can be compared to derive an objective measure of the therapeutic relationship.
This step includes a translation of the tools (English to French) and a redesign work of the original tools. Then, the study will include clinicians (at least 20) from two healthcare settings (CHU Sainte-Justine, and the CISSS-CA (Hotel-Dieu de Levis). After a presentation of the two tools during the Emergency Physicians' departmental meetings, the written comments about the prototype version will be collected. A revision of the prototypes is scheduled at the end of this step.
A delay in cord clamp for 45 seconds will be instituted in the delivery room. Placebo drug solution will be administered within 12hrs post-birth.